Abstract:SIGNIFICANCE STATEMENT:Renal fibrosis is a common pathologic process of progressive CKD. We have provided strong evidence that PGI 2 is an important component in the kidney injury/repairing process by reducing fibrosis and protecting renal function from declining. In our study, administration of a PGI 2 analog or selective PTGIR agonist after the acute injury ameliorated renal fibrosis. Our findings provide new insights into the role of PGI 2 in kidney biology and suggest that targeting PGI 2 /PTGIR may be a potential therapeutic strategy for CKD. BACKGROUND:Prostanoids have been demonstrated to be important modulators to maintain tissue homeostasis in response to physiologic or pathophysiologic stress. Prostacyclin (PGI 2 ) is a member of prostanoids. While limited studies have shown that PGI 2 is involved in the tissue injury/repairing process, its role in renal fibrosis and CKD progression requires further investigation. METHODS:Prostacyclin synthase ( Ptgis )-deficient mice, prostaglandin I 2 receptor ( Ptgir )-deficient mice, and an oral PGI 2 analog and selective PTGIR agonist were used to examine the role of PGI 2 in renal fibrosis in mouse models. We also analyzed the single-cell RNA-Seq data to examine the PTGIR -expressing cells in the kidneys of patients with CKD. RESULTS:Increased PTGIS expression has been observed in fibrotic kidneys in both humans and mice. Deletion of the PTGIS gene aggravated renal fibrosis and decline of renal function in murine models. A PGI 2 analog or PTGIR agonist that was administered after the acute injury ameliorated renal fibrosis. PTGIR, the PGI 2 receptor, deficiency blunted the protective effect of the PGI 2 analog. Fibroblasts and myofibroblasts were the major cell types expressing PTGIR in the kidneys of patients with CKD. Deletion of PTGIR in collagen-producing fibroblastic cells aggravated renal fibrosis. The protective effect of PGI 2 was associated with the inhibition of fibroblast activation through PTGIR-mediated signaling. CONCLUSIONS:PGI 2 is an important component in the kidney injury/repairing process by preventing the overactivation of fibroblasts during the repairing process and protecting the kidney from fibrosis and decline of renal function. Our findings suggest that PGI 2 /PTGIR is a potential therapeutic target for CKD.

Renal Prostaglandins in the Control of Renin1

Prostaglandins in Renovascular and Renal Hypertension

Direct Pro-Inflammatory Effects of Prorenin on Microglia.

Abstract 160: Angiotensin-(1-7) Decreases the Pro-inflammatory Effects of Prorenin in Hypothalamic Microglia

Prostaglandins and Renal Function

Abstract 17594: Brain Microglial Cytokines are Critical for Renin-Angiotensin-Aldoterone-System(RAAS)-Induced Neurogenic Hypertension

MICROGLIAL ACTIVATION BY THE BRAIN RENIN‐ANGIOTENSIN SYSTEM

The Relationship Between Heart Rate Variability and Prostaglandin E2 in Patients with Renal Insufficiencies.

Brain Microglial Cytokines are Critical for Renin-Angiotensin-Aldoterone-System(RAAS)-Induced Neurogenic Hypertension

Involvement of the Brain (Pro) Renin Receptor in Cardiovascular Homeostasis

Role of Renal Prostaglandins in Circulatory Homeostasis

Exaggerated prostaglandin biosynthesis and its influence on renal resistance in the isolated hydronephrotic rabbit kidney.

Arachidonate metabolism in renal injury

Renal Localization and Regulation of 15-Hydroxyprostaglandin Dehydrogenase.

Intra-Renal Factors in Renin Release

Prostanoid biosynthesis and mechanisms of action

Cellular Interactions between Vasopressin and Prostaglandins in the Mammalian Kidney

Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease.

Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor.

Abstract P002: Soluble (pro)renin Receptor Contributes To Angiotensin II-Induced Hypertension In Mice